重新审视非小细胞肺癌的新辅助治疗
晚期非小细胞肺癌(NSCLC)治疗进展迅速,而新辅助和辅助治疗发展相对滞后;早期阶段总生存获益的确立因需大型试验和长期生存数据而具有挑战性。靶向治疗和免疫治疗(单药或联合化疗)的多项新辅助试验为传统疗效参数(如RECIST缓解与病理缓解不一致)提供了独特见解,并拓展了生物标志物发现机会。随着试验终点进一步标准化及放射组学和数字病理学等新技术的应用,个体化风险分层新辅助治疗策略有望对早期NSCLC结局产生显著影响。
要点
- 早期NSCLC确立总生存获益具有挑战性,需大型试验和长期生存数据。
- 靶向和免疫新辅助试验揭示RECIST缓解与病理缓解存在不一致。
- 试验终点标准化及放射组学、数字病理学有望推动个体化风险分层新辅助治疗。
核心结论
- 个体化风险分层新辅助治疗策略有望对早期NSCLC的结局产生显著影响。
研究设计与样本
- 综述,总结新辅助和辅助治疗在早期NSCLC中的发展及多项新辅助试验(靶向治疗和免疫治疗,单药或联合化疗)的结果。
主要发现
- 靶向治疗和免疫治疗的新辅助试验(单药或联合化疗)为传统疗效参数提供了独特见解,如RECIST缓解与病理缓解之间的不一致。
- 这些试验拓展了生物标志物发现的机会。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite the rapidly evolving treatment landscape in advanced non-small-cell lung cancer (NSCLC), developments in neoadjuvant and adjuvant treatments have been nascent by comparison. Establishing overall survival benefit in the early-stage setting has been challenging because of the need for large trials and long-term survival data. Encouraged by improved treatment outcomes with a biomarker-driven approach in advanced NSCLC, and recognising the need to improve survival outcomes in early-stage NSCLC, there has been renewed interest in revisiting neoadjuvant strategies. Multiple neoadjuvant trials with targeted therapy and immunotherapy, either alone or in combination with chemotherapy, have yielded unique insights into traditional response parameters, such as the discordance between RECIST response and pathological response, and expanded opportunities for biomarker discovery. With further standardisation of trial endpoints across studies, coupled with the implementation of novel technologies including radiomics and digital pathology, individual risk-stratified neoadjuvant treatment approaches are poised to make a striking impact on the outcomes of early-stage NSCLC.
引用
- Saw SPL, Ong BH, Chua KLM, et al. Revisiting neoadjuvant therapy in non-small-cell lung cancer. Lancet Oncol. 2021. PMID: 34735819. doi:10.1016/S1470-2045(21)00383-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。